APLS
Apellis Pharmaceuticals, Inc.
Latest Form 4:Sale$8KbyDeLong Mark Jeffrey (Chief Business & Strat Officer) · filed Feb 13, 2026
Apellis Pharmaceuticals, Inc. (APLS) has 80 SEC Form 4 filings (207 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: May 14, 2026.
The most active filer is General Counsel Watson David O. with 8 filings. Insiders have net sold $2.8M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Cedric Francois
- Employees:705
- HQ:Waltham, MA, US
- IPO:2017-11-09
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7.2M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Business & Strat Officer | Sale | 368 | $8K | Feb 13 | SEC ↗ | |
| Chief Business & Strat Officer | Sale | 3,371 | $73K | Jan 23 | SEC ↗ | |
| Chief Scientific Officer | Sale | 5,928 | $129K | Jan 23 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,797 | $61K | Jan 23 | SEC ↗ | |
| General Counsel | Sale | 7,832 | $170K | Jan 23 | SEC ↗ | |
| VP/Chief Accounting Officer | Sale | 2,064 | $45K | Jan 23 | SEC ↗ | |
| Chief Financial Officer | Sale | 10,287 | $224K | Jan 23 | SEC ↗ | |
| Chief Technical Officer | Sale | 7,725 | $168K | Jan 23 | SEC ↗ | |
| Chief Executive Officer | Sale | 27,192 | $592K | Jan 23 | SEC ↗ | |
| Chief Medical Officer | Sale | 1,882 | $37K | Jan 21 | SEC ↗ | |
| VP/Chief Accounting Officer | Sale | 726 | $14K | Jan 21 | SEC ↗ | |
| Chief Technical Officer | Sale | 2,203 | $44K | Jan 21 | SEC ↗ | |
| Chief Scientific Officer | Sale | 909 | $18K | Jan 21 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,892 | $57K | Jan 21 | SEC ↗ | |
| Chief Business & Strat Officer | Sale | 1,334 | $26K | Jan 21 | SEC ↗ | |
| General Counsel | Sale | 2,475 | $49K | Jan 21 | SEC ↗ | |
| Chief Executive Officer | Sale | 8,182 | $162K | Jan 21 | SEC ↗ | |
Deschatelets PascalFirst filing | Chief Scientific Officer | Sale | 2,277 | $51K | Jan 15 | SEC ↗ |
Chopas James GeorgeFirst in 4 months | VP/Chief Accounting Officer | Sale | 873 | $19K | Jan 15 | SEC ↗ |
| Chief Financial Officer | Sale | 3,856 | $86K | Jan 15 | SEC ↗ | |
DeLong Mark JeffreyFirst filing | Chief Business & Strat Officer | Sale | 1,780 | $39K | Jan 15 | SEC ↗ |
Nicholson NurFirst filing | Chief Technical Officer | Sale | 2,618 | $58K | Jan 15 | SEC ↗ |
Francois CedricFirst filing | Chief Executive Officer | Sale | 10,186 | $226K | Jan 15 | SEC ↗ |
| General Counsel | Sale | 5,780 | $128K | Jan 15 | SEC ↗ | |
Baumal CarolineFirst filing | Chief Medical Officer | Sale | 3,020 | $77K | Jan 6 | SEC ↗ |
| General Counsel | Sale | 5,000 | $122K | Dec 18 | SEC ↗ | |
| General Counsel | Sale | 5,000 | $100K | Nov 18 | SEC ↗ | |
| Chief Financial Officer | Sale | 10,000 | $280K | Oct 23 | SEC ↗ | |
| General Counsel | Sale | 5,000 | $126K | Oct 17 | SEC ↗ | |
| Director | Sale | 31,092 | $738K | Oct 15 | SEC ↗ | |
| Director | Sale | 31,092 | $702K | Oct 2 | SEC ↗ | |
Dunlop A. SinclairFirst filing | Director | Sale | 31,092 | $714K | Sep 19 | SEC ↗ |
| General Counsel | Sale | 5,000 | $122K | Sep 18 | SEC ↗ | |
| VP/Chief Accounting Officer | Sale | 189 | $5K | Sep 17 | SEC ↗ | |
Watson David O.First filing | General Counsel | Sale | 20,000 | $523K | Sep 12 | SEC ↗ |
Sullivan Timothy EugeneFirst filing | Chief Financial Officer | Sale | 42,729 | $1.2M | Sep 10 | SEC ↗ |
Chopas James GeorgeFirst filing | VP/Chief Accounting Officer | Sale | 548 | $15K | Sep 3 | SEC ↗ |
Related companies
Apellis Pharmaceuticals, Inc. is in the Healthcare sector.